Changing winds: practice implications of acetaminophen regulations
Related Experiment Video
Updated: Jun 19, 2026

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
Andrew L Rogalski1, Kelly M Smith
1University of Kentucky Healthcare, Lexington, Kentucky 40536, USA.
Abstract:
The Food and Drug Administration (FDA) convened a joint meeting of 3 advisory committees in June 2009 to review and propose recommendations for reducing the incidence of acetaminophen-induced liver injury. The committee voted in favor of 7 of the 9 recommendations that will be taken to the FDA for executive review and action. The actions supported by the committee represent potentially sweeping changes to both over-the-counter and prescription acetaminophen-containing products. This article reviews the committee process, previous FDA actions on acetaminophen, and implications of the recommendations made for the orthopedic practitioner.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Dosage Regimen: Individualization
Pharmacokinetics in Pediatric Patients: Drug Excretion